Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia
Corresponding Author
Giovanni D'Arena
Hematology, P.O. S. Luca, ASL Salerno, Vallo della Lucania, Italy
Correspondence
Giovanni D'Arena, Hematology, P.O. S. Luca, 84078 Vallo della Lucania, ASL Salerno, Italy.
Email: [email protected]
Search for more papers by this authorSilvestro Volpe
Immunohematology Unit, AORN Giuseppe Moscati, Avellino, Italy
Search for more papers by this authorRachele Amodeo
Flow Cytometry Unit, Clinical Laboratory, Sant'Andrea Hospital, Roma, Italy
Search for more papers by this authorVirginia Tirino
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy
Search for more papers by this authorFiorella D'Auria
Laboratory of Clinical and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Search for more papers by this authorGiordano Annamaria
Hematology Unit and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
Search for more papers by this authorGiuseppe Pietrantuono
Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Search for more papers by this authorLuca Laurenti
Hematology Unit IRCCS Fondazione Policlinico Gemelli, Catholic University of “Sacred Heart”, Roma, Italy
Search for more papers by this authorAntonella Aiello
Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy
Search for more papers by this authorPellegrino Musto
Department of Emergency and Organ Transplantation, Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
Search for more papers by this authorCorresponding Author
Giovanni D'Arena
Hematology, P.O. S. Luca, ASL Salerno, Vallo della Lucania, Italy
Correspondence
Giovanni D'Arena, Hematology, P.O. S. Luca, 84078 Vallo della Lucania, ASL Salerno, Italy.
Email: [email protected]
Search for more papers by this authorSilvestro Volpe
Immunohematology Unit, AORN Giuseppe Moscati, Avellino, Italy
Search for more papers by this authorRachele Amodeo
Flow Cytometry Unit, Clinical Laboratory, Sant'Andrea Hospital, Roma, Italy
Search for more papers by this authorVirginia Tirino
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy
Search for more papers by this authorFiorella D'Auria
Laboratory of Clinical and Advanced Diagnostics, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Search for more papers by this authorGiordano Annamaria
Hematology Unit and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
Search for more papers by this authorGiuseppe Pietrantuono
Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Search for more papers by this authorLuca Laurenti
Hematology Unit IRCCS Fondazione Policlinico Gemelli, Catholic University of “Sacred Heart”, Roma, Italy
Search for more papers by this authorAntonella Aiello
Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy
Search for more papers by this authorPellegrino Musto
Department of Emergency and Organ Transplantation, Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
Search for more papers by this authorCONFLICT OF INTEREST
The authors have no competing interests.
REFERENCES
- 1Furstenau M, De Silva N, Eichhorst B, et al. Minimal residual disease assessment in CLL: ready for use in clinical routine? HemaSphere. 2019; 3(5): e287.
- 2Del Giudice I, Raponi S, Della Starza I, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019; 9: 689. doi:10.3389/fonc.2019.00689
- 3 European Medicines Agency. Guidelines on the Use of Minimal Residual Disease as an Endpoint in Chronic Lymphocytic Leukemia Studies. European Medicines Agency; 2014. Available online at: http://www.ema.europa.eu/documents/scientific-guideline/guideline-use-minimal-residue-disease-endopoint-chronic-lymphocytic-leukemia-studies_en.pdf
- 4Thompson M, Brandler D, Nabhan C, et al. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents. JAMA Oncol. 2018; 4: 394-400. doi:10.1001/jamaoncol.2017.2009
- 5Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, an supportive management of CLL. Blood. 2018; 131: 2745-2760.
- 6Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32: 23-33.
- 7Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21: 956-964.
- 8Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative on CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013; 27: 142-149.
- 9Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparametric flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016; 30: 929-936.
- 10Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021; 35(11): 3059-3072.
- 11Minervini CF, Cumbo C, Redavid I, et al. Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia. Sci Rep. 2021; 11(1): 17668. doi:10.1038/s41598-021-97198-3
Citing Literature
